XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31

EXAGEN INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$7.43−0.29 (-3.76%)

Close on Oct 19, 2026

Market cap: $179.54M
P/E (TTM): –
Dividend yield: –

Dividends

Exagen has not reported a dividend

No dividend per share appears in Exagen's annual filings since fiscal 2017.

Where these numbers come from

Parsed from the XBRL in Exagen's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is XGN.

Revenue growth20.8% · median 13.1%

Gross margin58.6% · median 45.0%

Operating margin-18.6% · median -92.0%

Net margin-26.6% · median -90.4%

Company	Revenue	Growth
CSTL	$357.28M	+3.2%
GRAL	$165.26M	+23.1%
BDSX	$102.94M	+34.5%
XGN	$71.12M	+20.8%
PSNL	$69.67M	-13.3%
MDXH	–	–

Company

Next earnings (est.): Nov 3, 2026, before open
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 220
Held by institutions: 34.1%
Auditor: BDO USA, P.C.
SEC CIK: 1274737

Advertisement
300 × 250